Physician profile
Christopher A Heeb
NPI 1700878162
$2,611.52
in general payments reported to CMS, 2019-2025
36 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $40.62 · 2021: $187 · 2022: $453 · 2023: $505 · 2024: $650 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $455.70 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $260.05 | 2024-2025 | Vowst |
| Pfizer INC. | $257.48 | 2019-2025 | |
| Lilly USA, LLC | $247.79 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $232.23 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $191.43 | 2020-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.44 | 2023-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $74.93 | 2019-2025 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $72.34 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.15 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $63.75 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Daiichi Sankyo INC. | $56.45 | 2022-2023 | Injectafer |
| Xeris Pharmaceuticals, INC. | $49.99 | 2024 | Gvoke Hypopen, Recorlev |
| Exact Sciences Corporation | $39.51 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $37.37 | 2023-2024 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $34.72 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $29.24 | 2019-2021 | |
| Almatica Pharma LLC | $28.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.57 | 2019-2022 | |
| Shield Therapeutics INC | $27.18 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.02 | 2023 | |
| Phathom Pharmaceuticals, INC. | $22.51 | 2024 | Voquezna |
| Biogen, INC. | $20.50 | 2021 | |
| Abbott Laboratories | $19.24 | 2021 | |
| Dynavax Technologies Corporation | $17.14 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.45 | 2024 | Camzyos |
| Abiomed | $15.06 | 2024 | Impella |
| Ethicon US, LLC | $14.69 | 2019 | |
| Axsome Therapeutics, INC. | $14.02 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $13.70 | 2023 | Airduo Digihaler |
| Biohaven Pharmaceuticals, INC. | $13.65 | 2021 | |
| Vanda Pharmaceuticals INC. | $13.61 | 2022 | |
| Boston Scientific Corporation | $13.61 | 2020 | |
| Astellas Pharma US INC | $13.56 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $13.39 | 2023 | Quviviq |
| Sanofi Pasteur INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Heeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.